A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
- Sponsor:
- SWOG
- Sponsor Study ID:
- MM1YA-S01
- CTO #:
- 104299
- NCT Number:
- NCT05554406
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Myeloid and Monocytic Leukemia
- Study Objectives:
- I. To compare measurable residual disease (MRD) negative complete remission (CR) rates between each of the experimental regimens and cytarabine + daunorubicin (7+3).
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Baratam, Praneeth, at baratamp@musc.edu
- Study Coordinator, Kelly, Sarah, at kellysar@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina